

**Omadacycline (PTK 0796) Publications/Posters/Oral Presentations**

<b>Publications</b>				
<b>Date</b>	<b>Journal</b>	<b>Citation</b>	<b>First Author</b>	<b>Title</b>
May, 2019	Antimicrob. Agents and Chemother.	Accepted, epub ahead of print	Lepak	<b><i>In vivo</i> Pharmacodynamics of Omadacycline against <i>Staphylococcus aureus</i> in the Neutropenic Murine Thigh Infection Model</b>
May, 2019	Diagnostic Micro. & Infect. Dis.	94(1):78-80	Fluit	<b>Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants</b>
May, 2019	Antimicrob. Agents and Chemother.	63:e02083-18	Overcash	<b>Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1 Study</b>
May, 2019	Antimicrob. Agents and Chemother.	63:e02522-18	Shoen	<b><i>In vitro</i> activities of omadacycline against rapidly growing mycobacteria</b>
Feb, 2019	J. Global Antimicrobial Resistance	Accepted, epub ahead of print	Huband	<b>Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017</b>
Feb, 2019	American Health & Drug Benefits	12(1):Supplement 1, S1-S12	LaPensee	<b>Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective</b>
Feb, 2019	American Health & Drug Benefits	12(1):Supplement 2, S13-S24	LaPensee	<b>Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections</b>
Feb, 2019	New England J of Medicine	380:517-27	Stets	<b>Omadacycline for Community-Acquired Bacterial Pneumonia</b>
Feb, 2019	New England J of Medicine	380:528-38	O'Riordan	<b>Omadacycline for Acute Bacterial Skin and Skin-Structure Infections</b>
Feb, 2019	Antimicrob. Agents and Chemother.	63:e01907-18	Kohlhoff	<b><i>In Vitro</i> Activity of Omadacycline against <i>Chlamydia pneumoniae</i></b>

<b>Publications</b>				
<b>Date</b>	<b>Journal</b>	<b>Citation</b>	<b>First Author</b>	<b>Title</b>
Feb, 2019	Antimicrob. Agents and Chemother.	63:e01581-18	Moura	<b>Omadacycline gut microbiome exposure does not induce <i>Clostridium difficile</i> proliferation or toxin production in a model that simulates the proximal, medial and distal human colon</b>
Dec, 2018	American Health & Drug Benefits	11(9):449-459	LaPensee	<b>Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections</b>
June, 2018	Diagnostic Micro. & Infect. Dis.	91(2):179-183	Pfaller	<b>Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Program (2014)</b>
Apr, 2018	Antimicrob. Agents and Chemother.	62:e02551-17	Goldstein	<b>Omadacycline: comparative <i>in vitro</i> activity against dog and cat bite wound isolates</b>
Apr, 2018	Antimicrob. Agents and Chemother.	62:e00047-18	Stapert	<b>The <i>In Vitro</i> Activity of Omadacycline and Comparators Against Anaerobic Bacteria</b>
Apr, 2018	Antimicrob. Agents and Chemother.	62: e02327-17	Pfaller	<b>Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016</b>
Feb, 2018	Antimicrob. Agents and Chemother.	62: e01487-17	Bundrant	<b>Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple Dose Regimens</b>
Feb, 2018	Antimicrob. Agents and Chemother.	62: e02057-17	Berg	<b>Pharmacokinetics and Safety of Omadacycline in Subjects With Impaired Renal Function</b>
Feb, 2018	Diagnostic Micro. & Infect. Dis.	90(2):143-147	Pfaller	<b>Activity of Omadacycline Tested against <i>Streptococcus pneumoniae</i> from a Global Surveillance Program (2014)</b>
Sept, 2017	Antimicrob. Agents and Chemother.	61: e01135-17	Gotfried	<b>Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells in Healthy Adult Subjects</b>

<b>Publications</b>				
<b>Date</b>	<b>Journal</b>	<b>Citation</b>	<b>First Author</b>	<b>Title</b>
May, 2017	Antimicrob. Agents and Chemother.	61: e02434-16	Steenbergen	<b><i>In Vitro and In Vivo Activity of Omadacycline Against Two Biothreat Pathogens: Bacillus anthracis and Yersinia pestis</i></b>
May, 2017	Antimicrob. Agents and Chemother.	61: e02368-16	Lepak	<b><i>In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model</i></b>
May, 2017	Antimicrob. Agents and Chemother.	61: e00018-17	Pfaller	<b><i>Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011</i></b>
May, 2017	Xenobiotica	47:8, 682-696	Flarakos	<b><i>Clinical disposition, metabolism and in vitro drug–drug interaction properties of omadacycline</i></b>
March, 2017	Antimicrob. Agents and Chemother.	61: e02411-16	Pfaller	<b><i>Activity of Omadacycline and Comparator Agents When Tested against Staphylococcus aureus from a Surveillance Program Conducted in North America and Europe</i></b>
March, 2017	J. Clin. Pharmacol.	57(3): 321-327	Tzanis	<b><i>Effect of Food on the Bioavailability of Omadacycline in Healthy Subjects</i></b>
Jan, 2017	Antimicrob. Agents and Chemother.	61: e01784-16	Lin	<b><i>Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline Following a Single Intravenous or Oral Dose of <sup>14</sup>C-omadacycline in Rats</i></b>
Dec, 2016	Bioorg. Med. Chem.	24(2016): 6409-6419	Tanaka	<b><i>Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic</i></b>
Dec, 2016	Antimicrob. Agents and Chemother.	60(12): 7431-7435	Sun	<b><i>A Randomized, Open-label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects</i></b>
Dec, 2016	Antimicrob. Agents and Chemother.	60(12): 7502-7504	Waites	<b><i>In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents Against Human Mycoplasmas and Ureaplasmas</i></b>
Oct, 2016	Future Microbiol.	11(11): 1421-1434	Villano	<b><i>Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections</i></b>
Sept, 2016	Antibiotics	5: 32	Heidrich	<b><i>The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome</i></b>

<b>Publications</b>				
<b>Date</b>	<b>Journal</b>	<b>Citation</b>	<b>First Author</b>	<b>Title</b>
Sept, 2016	Antimicrob. Agents and Chemother.	60(9): 5247-5253	Tanaka	<b><i>In Vitro and In Vivo</i> Assessment of Cardiovascular Effects with Omadacycline</b>
Nov, 2015	Antimicrob. Agents and Chemother.	59(11): 7044-7053	Honeyman	<b>Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline</b>
March, 2014	Antimicrob. Agents and Chemother.	58(3): 1279–1283	Draper	<b>Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline</b>
Feb, 2014	Antimicrob. Agents and Chemother.	58(2): 1127-1135	Macone	<b><i>In Vitro and In Vivo</i> Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline</b>
Nov, 2012	Antimicrob. Agents and Chemother.	56(11): 5650-5654	Noel	<b>A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
May 14-17, 2019	SAEM	88	Pollack	<b>Omacycline Treatment of Acute Bacterial Skin and Skin Structure Infections in Intravenous Drug Users</b>
Apr 13-16, 2019	ECCMID	O0304	Cornely	<b>Safety and Efficacy of Omacycline for Treatment of Community-acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections in Patients with Mild to Moderate Renal Insufficiency</b>
Apr 13-16, 2019	ECCMID	O0306	Pai	<b>Safety and Efficacy of Omacycline for Treatment of Acute Bacterial Skin and Skin Structure Infections by Patient Body Mass Index</b>
Apr 13-16, 2019	ECCMID	P0485	Ramirez	<b>Early Clinical Response and Clinical Stability as Predictors of Overall Clinical Response in Community-acquired Bacterial Pneumonia</b>
Apr 13-16, 2019	ECCMID	P1876	Huband	<b>In Vitro Activity of Omacycline and Comparators against Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
Apr 13-16, 2019	ECCMID	P1918	Pai	<b>Safety and Efficacy of Omadacycline by Body Mass Index in Patients with Community-acquired Bacterial Pneumonia</b>
Apr 13-16, 2019	ECCMID	P1943	Lakota	<b>Omadacycline Pharmacokinetics: Impact of Comorbidities</b>
Apr 13-16, 2019	ECCMID	P1944	Bhavnani	<b>Assessment of Pharmacokinetics-Pharmacodynamics to Support Omadacycline Dosing Regimens for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSI)</b>
Apr 13-16, 2019	ECCMID	P2011	Tzanis	<b>Omadacycline Hepatic Safety: Integrated Analysis of Randomized Controlled Phase III Trials</b>
Apr 13-16, 2019	ECCMID	P2288	LaPensee	<b>Incidence of emergency department visits and hospitalizations after outpatient treatment with an oral antibiotic among patients with acute bacterial skin and skin structure infections</b>
Dec 2-6, 2018	ASHP	4-048	LaPensee	<b>Cost-saving Opportunities Among Hospitalized Community-Acquired Pneumonia Patients Treated with Omadacycline, an Aminomethylcycline Antibiotic with IV and Oral Formulations, Compared to Ceftriaxone and Macrolide Therapy</b>
Dec 2-6, 2018	ASHP	4-049	LaPensee	<b>Cost-savings Analysis with Use of Omadacycline Among Hospitalized Community-Acquired Pneumonia Patients At Risk of <i>Clostridium difficile</i> Infection Being Treated with Moxifloxacin: Budget Impact Model Findings</b>
Oct 3-7, 2018	IDWEEK	1347	Abrahamian	<b>Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials</b>
Oct 3-7, 2018	IDWEEK	1356	Tzanis	<b>Improvement in Quality of Life for Adults with Acute Bacterial Skin and Skin Structure Infections Following Treatment with Omadacycline or Linezolid</b>
Oct 3-7, 2018	IDWEEK	1364	Mendes	<b>Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSI Clinical Trials</b>
Oct 3-7, 2018	IDWEEK	1374	Opal	<b>Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic</b>
Oct 3-7, 2018	IDWEEK	1377	Mendes	<b>Omadacycline In Vitro Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
Oct 3-7, 2018	IDWEEK	1462	Lodise	<b>Hospital Admission Patterns in Adult Patients with Community-acquired Bacterial Pneumonia who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score</b>
Sept 15-19, 2018	ERS	PA5465	Ramirez	<b>Impact of Age and Gender on Efficacy and Safety of Omadacycline versus Moxifloxacin in Community-acquired Bacterial Pneumonia</b>
Sept 4-7, 2018	ESCMID-ASM	51	Shoen	<b>In vitro activities of omadacycline against rapidly growing mycobacteria</b>
June 7-11, 2018	ASM Microbe	SATURDAY-624	VanScoy	<b>Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against <i>Haemophilus influenzae</i> Using A One-Compartment <i>In Vitro</i> Infection Model</b>
June 7-11, 2018	ASM Microbe	SATURDAY-625	Bhavnani	<b>Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) for <i>Streptococcus pneumoniae</i> (SP) and <i>Haemophilus influenzae</i> (HI)</b>
June 7-11, 2018	ASM Microbe	SATURDAY-626	Kohlhoff	<b><i>In Vitro</i> Activity of Omadacycline against <i>Chlamydia pneumoniae</i></b>
June 7-11, 2018	ASM Microbe	SATURDAY-627	Huband	<b>Omadacycline <i>In Vitro</i> Activity against Skin and Skin Structure, Respiratory, and Urinary Tract Pathogens Collected from the U.S. and Europe During the SENTRY Surveillance Program (2017)</b>
June 7-11, 2018	ASM Microbe	SATURDAY-628	Lakota	<b>Population Pharmacokinetic (PK) Analyses of Omadacycline Using Phase 1 and Phase 3 Data</b>
June 7-11, 2018	ASM Microbe	SATURDAY-701	Armstrong	<b>Efficacy of Omadacycline and Linezolid against Characterized Drug Resistant <i>S. aureus</i> from Combined Phase 3 ABSSSI Studies</b>
May 18-23, 2018	ATS	A4458	Ramirez (presented by McGovern)	<b>Early Clinical Response of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by PORT Risk Class: Results from the OPTIC Study</b>
Apr 21-24, 2018	ECCMID	P0271	Cornely	<b>Omadacycline Gastrointestinal Effects-An Integrated Safety Analysis from the Phase 3 ABSSSI and CABP Studies</b>
Apr 21-24, 2018	ECCMID	P0272	Garrity-Ryan	<b>Efficacy of Omadacycline Versus Moxifloxacin in Treating Subjects From Different Geographic Regions With Community-acquired Bacterial Pneumonia (CABP)</b>
Apr 21-24, 2018	ECCMID	P0273	O'Riordan	<b>Effects of Oral Omadacycline Versus Oral Linezolid on Lesion Size and Local Signs of ABSSSI in the Phase 3 OASIS-2 Study</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
Apr 21-24, 2018	ECCMID	P0274	Bassetti	<b>Efficacy of Oral Omadacycline Versus Linezolid for Treating Adult Subjects With ABSSSI: Analysis by Infection Type and Pathogen in the OASIS-2 Study</b>
Apr 21-24, 2018	ECCMID	P0275	Torres	<b>Omadacycline Versus Moxifloxacin in the Treatment of Adults with Community-acquired Bacterial Pneumonia (CABP): Efficacy Analysis According to EMA Requirements</b>
Apr 21-24, 2018	ECCMID	O0425	O'Riordan (presented by McGovern)	<b>A Phase-3 Randomized, Double-blind, Multi-centre Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects with ABSSSI (OASIS-2 Study)</b>
Apr 21-24, 2018	ECCMID	P1821	Dubois	<b>In Vitro Activity of Omadacycline Against Resistant Streptococcus pneumoniae And Haemophilus influenzae</b>
Apr 21-24, 2018	ECCMID	P1822	Huband	<b>Activity of Omadacycline and Comparators against Gram-Positive and -Negative Clinical Isolates (including resistant organism subsets) Collected in 2017 from Patients in European Medical Centres: SENTRY Surveillance Programme Results</b>
Apr 21-24, 2018	ECCMID	P1829	Dubois	<b><i>In Vitro</i> Activity of Omadacycline Against Resistant Staphylococcus aureus</b>
Oct 16-19, 2017	AMCP Nexus	L1	LaPensee	<b>Potential Cost-Saving Opportunities With Early Use of Omadacycline in Hospitalized Patients With ABSSSI With Inadequate Early Response to Vancomycin Plus Piperacillin-Tazobactam: Findings From a Decision-Analytic Budget Impact Model</b>
Oct 4-8, 2017	IDWEEK	861	McGovern	<b>Omadacycline, the First Aminomethylcycline</b>
Oct 4-8, 2017	IDWEEK	1223	Huband	<b><i>In Vitro</i> Activity of Omadacycline and Comparator Compounds against Gram-Positive Isolates Collected in the US During 2016 as Part of a Global Surveillance Program</b>
Oct 4-8, 2017	IDWEEK	1531	Lepak	<b><i>In vivo</i> Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the Murine Thigh Infection Model</b>
Oct 4-8, 2017	IDWEEK	1834	File	<b>Efficacy and Safety of Omadacycline in Chronic Kidney Disease (CKD) Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis From the OASIS Trial</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
Oct 4-8, 2017	IDWEEK	1838	Wilcox	<b>Efficacy and Safety of Omadacycline in Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and High Body Mass Index or Diabetes: A Subgroup Analysis From the OASIS Trial</b>
Oct 4-8, 2017	IDWEEK	1850	Lakota	<b>A Pharmacometric Comparison of Omadacycline and Tigecycline Epithelial Lining Fluid (ELF) Penetration</b>
Oct 4-8, 2017	IDWEEK	1875	Armstrong	<b>Analysis of the Microbiological data from the Omadacycline (OMC) Phase 3 Community-Acquired Bacterial Pneumonia (CABP) trial: The OPTIC study</b>
Oct 4-8, 2017	IDWEEK	1883	Stets	<b>A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study)</b>
Oct 4-8, 2017	IDWEEK	1885	Ohl	<b>Efficacy and Safety of Omadacycline in Intravenous Drug Using (IVDU) and Hepatitis C-Positive (HCV+) Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis from the OASIS Trial</b>
Oct 4-8, 2017	IDWEEK	1886	Darpo	<b>Cardiac Safety of Omadacycline in the IV/oral Phase 3 Acute Bacterial Skin and Skin Structure Infection (ABSSSI) and in the IV/oral Phase 3 Community-acquired Bacterial Pneumonia (CABP) Studies</b>
June 1-5, 2017	ASM Microbe	FRIDAY-239	LaPensee	<b>Characteristics of Hospitalized Patients with ABSSSI Treated with Vancomycin at Greatest Risk for Prolonged Hospital Length of Stay in an Integrated Delivery Network (IDN)</b>
June 1-5, 2017	ASM Microbe	FRIDAY-240	LaPensee	<b>Patient Populations at Greatest Risk for Hospital Readmission or Repeat Emergency Department Visit within 30 Days of Hospital Discharge among Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) Treated with Vancomycin</b>
June 1-5, 2017	ASM Microbe	SATURDAY-45	Huband	<b><i>In Vitro</i> Antibacterial Activity of Omadacycline and Comparators against Key Respiratory, Skin and Skin Structure and Urinary Tract Pathogens Collected from the United States and Europe During the 2016 SENTRY Worldwide Surveillance Program</b>
June 1-5, 2017	ASM Microbe	SATURDAY-46	Zhanel	<b><i>In Vitro</i> Antimicrobial Activity of Omadacycline, a New Aminomethylcycline, against Gram-Positive and Gram-Negative Bacterial Pathogens Isolated from Patients Attending Canadian Hospitals in 2015: The CANWARD Study</b>



<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
June 1-5, 2017	ASM Microbe	SATURDAY-197	LaPensee	<b>Patient Populations at Greatest Risk for Hospital Readmission or Repeat ED Visit within 30 Days of Hospital Discharge among Hospitalized Patients with Community-Acquired Pneumonia (CABP)</b>
June 1-5, 2017	ASM Microbe	SUNDAY-200	Overcash	<b>Pharmacokinetics and Safety of Omadacycline in Patients with Uncomplicated Urinary Tract Infections</b>
June 1-5, 2017	ASM Microbe	SUNDAY-201	Berg	<b>Pharmacokinetics and Safety of the Aminomethylcycline Antibiotic Omadacycline in Subjects with Impaired Renal Function</b>
June 1-5, 2017	ASM Microbe	SUNDAY-202	Bundrant	<b>Safety and Pharmacokinetic Assessments of the Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple Dose Regimens</b>
June 1-5, 2017	ASM Microbe	SUNDAY-261	Moura	<b>Effects of Omadacycline vs Moxifloxacin on Gut Microbiota Populations and <i>Clostridium difficile</i> Germination, Proliferation and Toxin Production in an <i>In Vitro</i> Model of the Human Gut</b>
June 1-5, 2017	ASM Microbe	SUNDAY-331	Holliday	<b>A Multi-Site Study Comparing a Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Omadacycline Using Non-Fastidious Gram Positive Organisms</b>
May 19-24, 2017	ATS	A3919	Gotfried	<b>Pulmonary Concentrations of the Aminomethylcycline Antibiotic Omadacycline</b>
May 19-24, 2017	ATS	A6856	Flamm	<b>Activity of Omadacycline When Tested Against Respiratory Pathogens <i>Streptococcus Pneumoniae</i>, <i>Haemophilus influenzae</i>, <i>Moraxella catarrhalis</i> and <i>Staphylococcus aureus</i> Isolated During 2016 from Medical Centers in the USA</b>
May 20-24, 2017	ISPOR	PRS43	Van Le	<b>Characteristics of Hospitalized Patients With Community-Acquired Bacterial Pneumonia (CABP) at Greatest Risk for Prolonged Hospital Length of Stay in an Integrated Delivery Network</b>
May 20-24, 2017	ISPOR	PRS44	LaPensee	<b>Hospital Admissions Patterns in Adult Patients With Community-Acquired Bacterial Pneumonia (CABP): Identification of Potentially Avoidable Hospital Admissions Through a Retrospective Database Analysis</b>
Apr 22-25, 2017	ECCMID	OS0606	O'Riordan (presented by Loh)	<b>A phase 3 randomized, double-blind, multi-centre study to compare the safety and efficacy of oral and IV omadacycline to linezolid for treating adult subjects with ABSSSI (the OASIS study)</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
Apr 22-25, 2017	ECCMID	P1252	O'Riordan	<b>Efficacy of Oral and IV Omadacycline vs. Linezolid for Treating Adult Subjects With ABSSSI: Analysis by Infection Type and Pathogen in the OASIS Study</b>
Apr 22-25, 2017	ECCMID	P1253	Huband	<b><i>In vitro</i> activity of omadacycline and comparators against Gram-negative bacterial isolates collected from patients in European medical centres (2016): results from the SENTRY antimicrobial surveillance programme</b>
Apr 22-25, 2017	ECCMID	P1254	Dubois	<b><i>In vitro</i> extracellular and intracellular activity of omadacycline against <i>Staphylococcus aureus</i></b>
Apr 22-25, 2017	ECCMID	P1255	O'Riordan	<b>Efficacy of omadacycline versus linezolid in treating ABSSSI patients from different geographic regions (OASIS trial)</b>
Apr 22-25, 2017	ECCMID	P1256	Overcash	<b>Effects of IV/oral omadacycline versus IV/oral linezolid on lesion size and local signs of ABSSSI in the phase 3 OASIS trial</b>
Apr 22-25, 2017	ECCMID	P1257	Gotfried	<b>Safety and Tolerability of IV Omadacycline (OMC) and Tigecycline (TGC) in Healthy Subjects in a Study to Assess Intra-Pulmonary Steady-State Concentrations</b>
Apr 22-25, 2017	ECCMID	P1262	Huband	<b><i>In vitro</i> activity of omadacycline and comparators against staphylococci, streptococci and enterococci (including resistant organism subsets) from patients in European medical centres during 2016: results from the SENTRY antimicrobial surveillance programme</b>
Apr 22-25, 2017	ECCMID	P1263	Thwaites	<b>The impact of non-standard test conditions on the <i>in vitro</i> activity of omadacycline by broth microdilution</b>
Apr 22-25, 2017	ECCMID	P1264	Stapert	<b>The <i>in vitro</i> activity of omadacycline and comparators against anaerobic bacteria</b>
Apr 22-25, 2017	ECCMID	P1265	LaPensee	<b>Economic impact of omadacycline among acute bacterial skin and skin structure infections (ABSSSIs) patients: cost-saving opportunities due to avoidable hospitalizations using an antibiotic with IV-to-oral switch capability</b>
Apr 22-25, 2017	ECCMID	P1266	LaPensee	<b>Cost-saving opportunities among hospitalized patients with acute bacterial skin and skin structure infections with omadacycline, a once-daily antibiotic with IV-to-oral transition capability, relative to current standard of inpatient care</b>

Posters and Oral Presentations				
Date	Conference	Presentation number	First Author	Title
Apr 22-25, 2017	ECCMID	OS1018	Horn	Comparison of Omadacycline (OMC) and Tigecycline (TGC) Pharmacodynamics (PD) in the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Subjects
Oct 26-30, 2016	IDWEEK	1827	Flamm	Activity of Omadacycline When Tested Against Gram-positive Bacteria Isolated from Patients in the USA During 2015 as Part of a Global Surveillance Program
June 16-20, 2016	ASM Microbe	MONDAY-001	Sweeney	Activity of Omadacycline Against Clinical Isolates of <i>Neisseria gonorrhoeae</i> , Including Ciprofloxacin-Resistant Isolates
June 16-20, 2016	ASM Microbe	MONDAY-509	Van Wart	Population Pharmacokinetics (PPK) of Omadacycline (OMC) Following Intravenous (IV) or Oral Administration and Evaluation of Phase 3 Sparse PK Sampling Strategies
June 16-20, 2016	ASM Microbe	MONDAY-510	Van Scoy	Evaluation of the <i>In Vitro</i> Activity Profile of Omadacycline Against <i>Haemophilus influenzae</i>
June 16-20, 2016	ASM Microbe	MONDAY-512	Hinshaw	Post-antibiotic Effect of Omadacycline Against Target Pathogens
June 16-20, 2016	ASM Microbe	MONDAY-518	Villano	<i>In Vitro</i> Protein Binding with Omadacycline, a First in Class Aminomethylcycline Antibiotic
June 16-20, 2016	ASM Microbe	MONDAY-519	Tzanis	Effect of Food on the Bioavailability of Omadacycline in Healthy Volunteers
June 16-20, 2016	ASM Microbe	MONDAY-551	Dubois	<i>In Vitro</i> Intracellular Activity of Omadacycline against <i>Legionella pneumophila</i>
June 16-20, 2016	ASM Microbe	MONDAY-552	Diehl	<i>In Vitro</i> Activity of Omadacycline Against <i>Escherichia coli</i> Biofilms
June 16-20, 2016	ASM Microbe	MONDAY-567	Tracjewski	Omadacycline (PTK0796) Spectrum of Activity from 2003 through 2015
April 9-12, 2016	ECCMID	P1324	Chilton	Effects of omadacycline on gut microbiota populations and <i>Clostridium difficile</i> germination, proliferation and toxin production in an <i>in vitro</i> model of the human gut
April 9-12, 2016	ECCMID	P1323	Dubois	<i>In Vitro</i> Bacterial and Intracellular Activity of Omadacycline against <i>Legionella pneumophila</i>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
April 9-12, 2016	ECCMID	P1317	Flamm	<b>Omadacycline activity tested against European bacterial isolates from a combined 2010-2011 Global Surveillance program</b>
April 9-12, 2016	ECCMID	P1322	Hawser	<b>Bactericidal activity of omadacycline, a novel aminomethylcycline</b>
April 9-12, 2016	ECCMID	P1325	Kim	<b>Activity and Efficacy of Omadacycline against <i>Clostridium difficile</i></b>
April 9-12, 2016	ECCMID	P1318	Tanaka	<b>Effect of Age and Gender on the Pharmacokinetics of the Oral and IV Omadacycline, A New Class of Aminomethylcyclines</b>
April 9-12, 2016	ECCMID	P1326	Tanaka	<b>A Pooled Analysis of Two Randomized Multicenter, Evaluator-Blind Studies Comparing the Safety and Efficacy of Omadacycline and Linezolid for the Treatment of Complicated Skin and Skin Structure Infections</b>
April 9-12, 2016	ECCMID	P1319	Tanaka	<b>Single and Multiple Dose Pharmacokinetics and Tolerability of Intravenous Omadacycline in Healthy Volunteers</b>
April 9-12, 2016	ECCMID	P1320	Van Wart	<b>Population Pharmacokinetics (PPK) of Omadacycline Following Intravenous or Oral Administration to Phase 1 Subjects</b>
April 9-12, 2016	ECCMID	P1321	Villano	<b>Omadacycline, an Aminomethylcycline Antibiotic, Has No Effect on QT/QTc Intervals in Healthy Subjects</b>
Sept 17-21, 2015	ICAAC	C-554	Flamm	<b>Activity of Omadacycline Tested against <i>Streptococcus pneumoniae</i> from a Global Surveillance Program (2014)</b>
Sept 17-21, 2015	ICAAC	C-614	Flamm	<b>Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Program (2014)</b>
Sept 17-21, 2015	ICAAC	F-289	Flamm	<b>Activity of Omadacycline Tested against <i>Staphylococcus aureus</i> from a Global Surveillance Program (2014)</b>
Sept 17-21, 2015	ICAAC	D-194	Traczewski	<b>Quality Control Parameters for Broth Microdilution and Agar dilution Susceptibility Tests of Omadacycline (formerly PTK-0796) against <i>B. fragilis</i> ATCC 25285, <i>B. thetaiotaomicron</i> ATCC 29741, <i>E. lenta</i> ATCC 43055, and <i>C. difficile</i> ATCC 700057 Using Fresh Media</b>
Sept 17-21, 2015	ICAAC	D-195	Traczewski	<b>Omadacycline (formerly PTK-0796) In Vitro Spectrum of Activity and Confirmation of Disk Mass Using Fresh Media for MIC Testing</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
Sept 17-21, 2015	ICAAC	D-1140	Traczewski	<b>Quality Control Parameters for Omadacycline Minimum Inhibitory Concentration (MIC) Susceptibility Tests.</b>
Sept 17-21, 2015	ICAAC	F-770	DuBois	<b><i>In Vitro</i> Activity of Omadacycline Against <i>Legionella pneumophila</i></b>
Feb 25-27, 2013	ASM Biodefense	253(G)	Draper	<b><i>In Vitro</i> Activity of Omadacycline (OMC) against Biothreat Bacteria</b>
Sept 9-12, 2012	ICAAC	A-1282	Ting	<b>Pharmacokinetics of Omadacycline (PTK0796) in Subjects with Hepatic Impairment</b>
Sept 9-12, 2012	ICAAC	A-1281	Sun	<b>Pharmacokinetics of [14C]-labeled Omadacycline (PTK 0796) in Healthy Male Subjects</b>
Mar 31- Apr 3, 2012	ECCMID	P694	Noel	<b>Safety and efficacy of PTK 0796 (Omadacycline) as treatment of complicated skin and soft tissue infection (cSSTI)</b>
Mar 31- Apr 3, 2012	ECCMID	P1422	Hanna	<b>Metabolic Stability of PTK 0796 (Omadacycline)</b>
Mar 31- Apr 3, 2012	ECCMID	P1423	Sun	<b>A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects</b>
Mar 31- Apr 3, 2012	ECCMID	P1424	Hanna	<b>Lack of Interaction of PTK 0796 (Omadacycline) with Human Transporter</b>
Mar 31- Apr 3, 2012	ECCMID	P1449	Flamm	<b>Antimicrobial Activity of PTK 0796 (Omadacycline) and Comparator Agents Against Contemporary Pathogens Commonly Associated with Community-Acquired Respiratory Tract Infections Collected During 2011 from the European Union</b>
Mar 31- Apr 3, 2012	ECCMID	P1450	Sader	<b>Antimicrobial Activity of PTK 0796 (Omadacycline) Tested against Gram-positive Organisms Isolated from European Hospitals in 2011</b>
Sept 17-20, 2011	ICAAC	C1-609	Ruzin	<b>Omadacycline (PTK796) Mechanism of Action Studies by Using <i>In Vitro</i> Protein Synthesis Inhibition Assay and Molecular Modeling</b>
May 7-10, 2011	ECCMID	P1528	Hait	<b>In a Phase 2 Complicated Skin and Soft Tissue Infections Trial, Outcomes Assessed Early in the Course of Therapy were Consistent with Outcomes 10-17 Days After Completing Therapy with Either Omadacycline (OMC; PTK796) or Linezolid</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
May 7-10, 2011	ECCMID	P1074	Leahy	<b>Comparative Efficacy of Omadacycline (PTK796) in Lethal <i>Streptococcus pneumoniae</i> and <i>Staphylococcus aureus</i> Pneumonia Models</b>
May 7-10, 2011	ECCMID	P1141	Macone	<b><i>In vitro</i> Activity of Omadacycline (PTK796) in Broth Plus Lung Surfactant or Human Serum</b>
Sept 12-15, 2010	ICAAC	B-069	Yu	<b>Efficacy of PTK796 in a Rat MRSA Infected Endocarditis (IE) Model</b>
Sept 12-15, 2010	ICAAC	C1-1413	Ruzin	<b>Studies on the Mechanism of Resistance to PTK796 in <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i></b>
Sept 12-15, 2010	ICAAC	E-1569	Biedenbach	<b><i>In Vitro</i> Evaluation of PTK 0796 Activity Tested against <i>Staphylococcus aureus</i>, Including Hospital- and Community-Associated MRSA Strains from the USA and Europe</b>
Sept 12-15, 2010	ICAAC	E-1588	Sader	<b>Antimicrobial Activity of PTK 0796 Tested against Gram-Positive Organisms Causing Bloodstream Infections in 2009</b>
Sept 12-15, 2010	ICAAC	K-124	Ting	<b>Pharmacokinetics of Intravenous and Oral PTK796, A New Aminomethylcycline Antibiotic</b>
Sept 12-15, 2010	ICAAC	L1-1760	Macone	<b>Identification and Susceptibility of Pathogens Isolated from Patients with Complicated Skin and Skin Structure Infections (cSSSI): Results of a PTK0796 (PTK) Phase 2 Clinical Trial</b>
Oct 25-28, 2008	ICAAC	L-1515b	Arbeit	<b>Safety and Efficacy of PTK 0796: Results of the Phase 2 Study in Complicated Skin and Skin Structure Infections Following IV and Oral Step Down Therapy</b>
Sept 27-30, 2006	ICAAC	F1-1971	Smith	<b>Antistaphylococcal Activity of MK-2764 / PTK 0796 Compared to Other Agents</b>
Sept 27-30, 2006	ICAAC	F1-1974	Craig	<b><i>In Vivo</i> Pharmacodynamics of MK-2764 / PTK 0796 Against Various Gram-positive and Gram-negative Bacteria in the Thighs of Neutropenic and Normal Mice</b>
Sept 27-30, 2006	ICAAC	F1-1972	DuBois	<b><i>In Vitro</i> Activity of MK-2764 / PTK 0796 Against <i>Legionella</i> spp.</b>
Sept 27-30, 2006	ICAAC	F1-1973	Tessier	<b>Pharmacokinetic/Pharmacodynamic Profile of MK-2764 / PTK 0796 against <i>S. pneumoniae</i> in a Murine Pneumonia Model</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
May 1-4, 2004	ECCMID	P926	Macone	<b>Potent activity of BAY 73-7388, a Novel Aminomethylcycline, Against Susceptible and Resistant Gram-positive and Gram-negative Organisms</b>
May 1-4, 2004	ECCMID	P928	Endermann	<b>BAY 73-7388 is Highly Efficacious in Animal Models of Intraabdominal Infections Caused by a Range of Aerobic and Anaerobic Organisms, Including VRE</b>
May 1-4, 2004	ECCMID	P930	Broetz-Oesterhelt	<b>Superior Efficacy of BAY 73-7388, a Novel Aminomethylcycline, Compared with Linezolid and Vancomycin in Murine Sepsis Caused by Susceptible or Multiresistant Staphylococci</b>
May 1-4, 2004	ECCMID	P925	Bhatia	<b>Activity of BAY 73-7388, a Novel Aminomethylcycline, and Other Novel Antibiotic Classes Against Resistant Bacteria <i>In Vitro</i></b>
May 1-4, 2004	ECCMID	P927	McKenney	<b>BAY 73-7388, a Novel Aminomethylcycline, Exhibits Potent Efficacy in Pulmonary Murine Models of Infection</b>
May 1-4, 2004	ECCMID	P929	Ladel	<b>BAY 73-7388 Demonstrates Greater Activity than Linezolid in a Range of Murine Models of Skin and Soft Tissue Infection</b>
May 1-4, 2004	ECCMID	P931	Endermann	<b>BAY 73-7388, a Novel Aminomethylcycline, is Highly Active <i>In Vivo</i> in a Murine Model of Pneumococcal Pneumonia</b>
Sept 14-17, 2003	ICAAC	F-751	Weir	<b>The Mechanism of Action of PTK 0796 (BAY 73-6944)</b>
Sept 14-17, 2003	ICAAC	F-752	Weir	<b>The Activity of PTK 0796 (BAY 73-6944) Against Tetracycline Resistance</b>
Sept 14-17, 2003	ICAAC	F-753	Traczewski	<b>PTK 0796 (BAY 73-6944): <i>In Vitro</i> Potency and Spectrum of Activity Compared to Ten Other Antimicrobial Compounds</b>
Sept 14-17, 2003	ICAAC	F-754	Macone	<b><i>In Vitro</i> Activity of PTK 0796 (BAY 73-6944) Against Gram-Positive and Gram-Negative Organisms</b>
Sept 14-17, 2003	ICAAC	F-755	Bhatia	<b>PTK 0796 (BAY 73-6944) and other Novel Tetracycline Derivatives Exhibiting Potent <i>in vitro</i> and <i>in vivo</i> Activities Against Antibiotic Resistant Gram-Positive Bacteria</b>
Sept 14-17, 2003	ICAAC	F-756	Traczewski	<b>PTK 0796 (BAY 73-6944): Effects of Environmental Variation on MICs and Confirmation of Disk Mass</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
Sept 14-17, 2003	ICAAC	F-757	McKenney	<b>Evaluation of PTK 0796 (BAY 73-6944) in Experimental Models of Infections Caused by Gram-Positive and Gram-Negative Pathogens</b>
Sept 14-17, 2003	ICAAC	F-758	McKenney	<b>The Efficacy of PTK 0796 (BAY 73-6944) in Murine Models of <i>Streptococcus pneumoniae</i> Infections</b>
Sept 14-17, 2003	ICAAC	F-759	Cannon	<b>Pharmacokinetics of PTK 0796 (BAY 73-6944) in Mouse, Rat and Cynomolgus Monkey</b>
Sept 14-17, 2003	ICAAC	F-760	Chaturvedi	<b><i>In Vitro</i> Assessment of Plasma Protein Binding and Metabolic Stability of PTK 0796 (BAY 73-6944)</b>